Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio Pharma (BBIO) shares rose 24% over the past three months, outpacing the S&P 500’s 0.7% gain during the same period. The rally has investors focused on whether momentum in commercialization and the pipeline can justify further upside, even as valuation looks rich and execution risk remains. BBIO’s stock is up 71.4% over the past year, versus 6.6% for its Zacks sub-industry and 12.4% for the Zacks Medical sector. A key driver is Attruby, which generated $403 million in U.S. sales in the first half of 2026 and $362.4 million in 2025, while ATTR-CM patient numbers in the U.S. exceeded 50,000 in 2025.